Morris P, Leach A
Menzies School of Health Research, Ear Health and Education Unit, Royal Darwin Hospital, Block 4, PO Box 41096, Darwin, Northern Territory, Australia, 0811.
Cochrane Database Syst Rev. 2007 Jul 18(3):CD001094. doi: 10.1002/14651858.CD001094.pub2.
Nasal discharge (rhinosinusitis) is extremely common in children. It is the result of inflammation of the mucosa of the upper respiratory tract, and is usually due to either infection or allergy. Infections may be caused by bacteria.
To determine the effectiveness of antibiotics versus placebo or standard therapy in treating children with persistent nasal discharge (rhinosinusitis) for at least 10 days.
In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2005) which includes the ARI Group's specialised trials register; MEDLINE (1966 to April Week 3, 2005) EMBASE (1997 to December 2004), and the references of relevant articles were searched. Authors and pharmaceutical companies were contacted.
All randomised controlled trials that compared antibiotics versus placebo or standard therapy. Trials which included the use of other medications were included if all participants were allowed equal access to such medications or if the additional or alternative therapies were regarded as ineffective. Trials that only combined or compared antibiotics with surgery, or sinus puncture and lavage, were not included in the review.
Data were extracted by a single author for the following eight outcomes: overall clinical failure (primary outcome), failure to cure, failure to improve, clinical improvement, time to resolution, complications, side-effects and bacteriologic failure. For the dichotomous outcome variables of each individual study, proportional and absolute risk reductions were calculated using a modified intention-to-treat analysis. The summary weighted risk ratio and 95% confidence interval (CI) (fixed effect model) were calculated using the inverse of the variance of each study result for weighting (Cochrane statistical package, RevMan version 4.2).
A total of six studies involving 562 children compared antibiotics with placebo or standard therapy. All studies were randomised but most were still susceptible to bias. Five of the studies were conducted in emergency, allergy or ENT clinics. Four of the studies required children to have x-ray changes consistent with sinusitis. Only the primary outcome (overall clinical failure) was reported in all studies. Around 40% of all randomised children did not have a clinical success documented when reviewed two to six weeks after randomisation. The control event rate varied from to 22 to 71% (mean 46%). The risk ratio estimated using a fixed effects model was 0.75 (95% CI 0.61 to 0.92). There was no evidence of statistical heterogeneity. Side effects (sufficient to cease treatment) occurred in 4 of 189 control group children (four studies). More children treated with antibiotics had side effects (17 of 330), but this difference was not statistically significant (RR 1.75, 95% CI 0.63 to 4.82).
AUTHORS' CONCLUSIONS: For children with persistent nasal discharge or older children with radiographically confirmed sinusitis, the available evidence suggests that antibiotics will reduce the probability of persistence in the short to medium-term. The benefits appear to be modest and around eight children must be treated in order to achieve one additional cure (number needed to treat (NNT) 8, 95% CI 5 to 29). No long term benefits have been documented. These conclusions are based on a small number of small randomised controlled trials and may require revision as additional data become available.
鼻分泌物(鼻窦炎)在儿童中极为常见。它是上呼吸道黏膜炎症的结果,通常由感染或过敏引起。感染可能由细菌导致。
确定抗生素与安慰剂或标准疗法相比,在治疗持续鼻分泌物(鼻窦炎)至少10天的儿童中的有效性。
在本次更新的综述中,我们检索了Cochrane对照试验中心注册库(CENTRAL)(《Cochrane图书馆》2005年第1期),其中包括ARI小组的专业试验注册库;MEDLINE(1966年至2005年4月第3周)、EMBASE(1997年至2004年12月),并检索了相关文章的参考文献。还联系了作者和制药公司。
所有比较抗生素与安慰剂或标准疗法的随机对照试验。如果所有参与者都能平等获得其他药物,或者额外或替代疗法被认为无效,则纳入包括使用其他药物的试验。仅将抗生素与手术、或鼻窦穿刺和灌洗联合或比较的试验不纳入本综述。
由一位作者提取以下八个结局的数据:总体临床失败(主要结局)、未治愈、未改善、临床改善、症状缓解时间、并发症、副作用和细菌学失败。对于每个个体研究的二分结局变量,使用改良的意向性分析计算比例和绝对风险降低率。使用每个研究结果方差的倒数进行加权,计算汇总加权风险比和95%置信区间(CI)(固定效应模型)(Cochrane统计软件包,RevMan 4.2版)。
共有六项涉及562名儿童的研究将抗生素与安慰剂或标准疗法进行了比较。所有研究均为随机研究,但大多数仍易受偏倚影响。其中五项研究在急诊、过敏或耳鼻喉科诊所进行。四项研究要求儿童有与鼻窦炎一致的x光改变。所有研究仅报告了主要结局(总体临床失败)。在随机分组后两至六周进行复查时,约40%的随机分组儿童没有记录到临床治愈。对照事件发生率在22%至71%之间(平均46%)。使用固定效应模型估计的风险比为0.75(95%CI 0.61至0.92)。没有统计学异质性的证据。189名对照组儿童中有4名(四项研究)出现副作用(严重到足以停止治疗)。接受抗生素治疗的儿童出现副作用的更多(330名中有17名),但这种差异无统计学意义(RR 1.75,95%CI 0.63至4.82)。
对于持续性鼻分泌物的儿童或影像学确诊鼻窦炎的大龄儿童,现有证据表明抗生素在短期至中期会降低病情持续的可能性。益处似乎不大,大约每治疗八名儿童才能多治愈一名(需治疗人数(NNT)8,95%CI 5至29)。尚无长期益处的记录。这些结论基于少数小型随机对照试验,可能会随着更多数据的获得而需要修订。